Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 8:24:1408-1416.
doi: 10.12659/msm.908971.

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies

Xiuhua Kang  1 , Li Zhou  2 , Ya-Mei Jian  3 , Shao-An Lan  2 , Fei Xu  1
Affiliations

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies

Xiuhua Kang et al. Med Sci Monit. .

Abstract

BACKGROUND Human lung cancer is still the leading cause of cancer-related mortality around the world, although a variety of new therapies have been used in the treatment of this disease. Antibody-drug conjugate (ADC) has revolutionized the field of cancer therapy in recent decades. Unlike traditional chemotherapy that damages the healthy cells, ADC first utilizes monoclonal antibodies to bind tumor-specific antigen targets and then deliver a highly potent cytotoxic agent to kill tumor cells. Thus, ADC can benefit cancer patients because this drug has less severe adverse effects. MATERIAL AND METHODS One type of ADC for non-small cell lung cancer (NSCLC) was designed in this study: Erbitux-vc-PAB-MMAE. It is a mouse/human chimeric monoclonal antibody, Erbitux, conjugating to the tubulin inhibitor auristatin. The efficacy of ADC was investigated through in vitro and in vivo studies. RESULTS Our in vitro study demonstrated that Erbitux-vc-PAB-MMAE could effectively inhibit proliferation of human lung cancer A549 cells, and arrested cell cycle at G2/M phase. In a mouse xenograft model, the results indicated that Erbitux-vc-PAB-MMAE could be exactly delivered to tumor tissues, and effectively inhibited tumor growth via promoting apoptosis of cancer cells. CONCLUSIONS The antibody portion of an ADC drug (Erbitux) was used as a vector to bring the effector molecule (tubulin inhibitor MMAE) to the targeted tumor tissue. This antibody-drug conjugate can exert a strong anti-tumor effect.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The cell cycle results with different concentrations of ADC, Cetuximab, and Cisplatin. Most cells in the control group are in G1 phase. In ADC groups (0.0134 mmol/L and 0.0267 mmol/L), most cells are in G2/M phase. In Cetuximab groups (0.0067 mmol/L and 0.0134 mmol/L) and Cisplatin groups (1.33 mmol/L and 2.66 mmol/L), most cells are in G1 phase.
Figure 2
Figure 2
The average tumor sizes (mean ±SD) of each group before and after administration of drugs (mm3, n=5).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19:e43–e55. - PubMed
    1. Cho JH. Immunotherapy for non-small-cell lung cancer: Current status and future obstacles. Immune Netw. 2017;17:378–91. - PMC - PubMed
    1. Moek KL, de Groot DJA, de Vries EGE, Fehrmann RSN. The antibody-drug conjugate target landscape across a broad range of tumour types. Ann Oncol. 2017;28:3083–91. - PubMed
    1. Willuda J, Linden L, Lerchen HG, et al. Preclinical antitumor efficacy of BAY 1129980-a novel auristatin-based anti-C4.4A (LYPD3) antibody-drug conjugate for the treatment of non-small cell lung cancer. Mol Cancer Ther. 2017;16:893–904. - PubMed
    1. Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs; 2018. [Epub ahead of print] - PMC - PubMed

MeSH terms